Top Picks For 2022: Madrigal Pharmaceuticals By: TalkMarkets January 22, 2022 at 16:15 PM EST Madrigal Pharmaceuticals is poised to deliver positive Phase III data in 2022 for resmetirom, its best-in-class NASH (nonalcoholic steatohepatitis) compound. Read More >> Related Stocks: Madrigal Pharmaceuticals Inc
